Dose comparison of Bredinin on rheumatoid arthritis: A multicenter, lon-term administration post-marketing surveillance study.

Mizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis

“…After 24 weeks of MZR treatment, incidence of patients with adverse reactions was statistically higher in 300 mg/day group (27.1%) than in the 150 mg/day group (15.5%) ( P < 0.01). According to a report from post­marketing surveillance, however, no statistical difference was observed between the two groups (1.3 and 7.1%, respectively) 27 …”

Inhibitory effect of mizoribine on matrix metalloproteinase-1 production in synovial fibroblasts and THP-1 macrophages

“…40 Furthermore, administration of 25 mg/kg per day of MZR induced only mild reduction of splenic lymphocytes, and even 100 mg/kg per day of MZR did not decrease the number of bone marrow cells in mice. 41 In our study, the dose-dependent inhibitory effect of MZR to MMP-1 production was recognized without affecting the cell forms and number of dead cells.…”

“…11 Mizoribine was approved in Japan for the clinical treatment of RA in 1992 after the marked amelioration of adjuvant arthritis via the suppression of T-cell function was demonstrated in rats 22 and a low incidence of adverse clinical effects was reported. 23 Moreover, MZR treatment was reported to improve bone lesions in the hind legs of animals with adjuvant arthritis. 24 Here, we examined whether MZR could inhibit MMP-1 and MMP-3 production in stimulated SFs and macrophage-like cells.…”